4,000 Strong: Celebrating Our Growing Community in Precision Immunotherapy

Immunopeptidomics is at the heart of everything we do at Alithea Bio. We are proud to announce that our community has officially surpassed 4,000 followers on LinkedIn, marking a significant milestone for our team and the field of precision immunotherapy.
While this number is a major achievement, it represents something much larger: a collective shift toward more precise, data-driven approaches in oncology. Our network now includes thousands of researchers and industry leaders focused on the same goal—developing safer treatments through advanced immunopeptidomics.

The Role of Immunopeptidomics in Target Discovery
At Alithea, we believe that the future of medicine lies in the quality of the data. From our HLA-Compass database to our advanced mass spectrometry workflows, we are committed to moving beyond traditional, manual methodologies.
Reaching 4,000 peers allows us to further our mission in immunopeptidomics by:

Advancing Target Discovery: Sharing insights that help identify unique HLA-peptides with higher accuracy.

Reducing Toxicity: Engaging in vital conversations about safety in TCR-T and CAR-T therapies as discussed in recent Journal of Commercial Biotechnology reports.

Optimizing Workflows: Streamlining high-sensitivity data collection to accelerate the transition from the bench to the clinic.

The Future of Data-Driven Research
As we expand our operations—from our laboratory in Berlin to our partnerships across the globe—your engagement fuels our innovation. We are dedicated to remaining at the forefront of the biotech industry, providing the deep-tier data required to solve the most complex challenges in cancer research through modern immunopeptidomics.
Thank you for being part of our 4,000-strong network. We look forward to the next chapter of discovery together.